pharma news today glp-1 obesity Market Overview: Agonists and the Market | Blog New weight-loss drugs surge in

DIRKO, double incretin receptor knockout

Supporting the body's own hormone response, through diet, lifestyle, and evidence-based supplementation, is a more sustainable approach than trying to replicate GLP-1 synthetically

Free-Range or Pasture-Raised

Last week, the ABC revealed that doctors were warning people not to take drugs labelled as "retatrutide" after seeing multiple cases of life-threatening illness, including acute liver failure

However, selective NaV1.7 inhibitors have repeatedly failed in the clinic, and recent studies across multiple programs point to on-target autonomic and cardiovascular liabilities

Kato M, Tani T, Terahara N, Tsuda T